Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

Phase 2

• Conditions: Aging
• Interventions: Drug: Dasatinib plus Quercetin

• Registration Number: NCT04946383
• Lead Sponsor: TruDiagnostic

Brief Summary

Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns' epigenetic biological aging. The patients are being tested at baseline, halfway point, and after the trial period.

Detailed Description

This is a prospective non-randomized clinical study of 20-25 patients to evaluate the effectiveness of Quercetin and Dasatinib supplements on the patient's epigenetic aging rate. The investigators predict that Quercetin and Dasatinib combined will slow cell proliferation and thus decelerate the rate of aging.

There is evidence that Quercetin and Dasatinib slows cell proliferation and decelerates aging and the risk of age-related diseases. The aim of this pilot study is to evaluate the safety, efficacy and feasibility of Quercetin and Dasatinib as an effective treatment option to improve clinical care of healthy individual's epigenetic aging rate thus prolonging longevity.

Despite considerable effort, successful treatment of reversing one's biological age has been shown to be a difficult therapeutic challenge. There is evidence that Dasatinib+Quercetin(Quercetin and Dasatinib) is a safe and effective treatment option to improve clinical care of healthy individual's biological age. Studies have shown that Dasatinib+Quercetin slows cell proliferation and decelerates aging and the risk of age-related diseases.

Study Timeline

• Study Start: 2020-12-16
• Study First Submitted: 2021-06-11
• Study First Submitted QC: 2021-06-29
• Study First Posted: 2021-06-30
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-02
• Last Update Posted: 2021-08-03
• Primary Completion: 2021-12-31
• Study Completion: 2022-06-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Men and women
• Ages 40 and older
• Patient must be able to comply with treatment plan and laboratory tests

Exclusion Criteria

• Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision
• No immune system issues or immunodeficiency disease
• No history of viral illness which could be reactivated by immune down regulation
• Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke)
• Diagnosis of a transient ischemic attack in the 6 months prior to screening
• Patients infected with hepatitis, C or HIV
• Patients with Body Mass Index (BMI) > 40 kg/m2
• Presence of active infection 9. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study
• Unable or unwilling to provide required blood sample for testing
• As for the male-participants they are recommended to avoid fertilization for the first 6 months after the clinical trial.
• If the patient has previously used Quercetin and Dasatinib.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Quercetin and Dasatinib supplements	Dasatinib plus Quercetin	500mg Quercetin and 50mg Dasatinib oral capsules on Monday, Tuesday, Wednesday (3 days in a row) per month for the duration of 6 months.

Primary Outcome Measures

Name	Time	Method
Epigenetic Age Test	Change from baseline to 6 months

Secondary Outcome Measures

Name	Time	Method
Examining Methylation changes	Change from baseline to 6 months	Methylation analysis via the Illumina 850k epic array. Methylation will be assessed at 850,000 spots on the DNA, these are located on CpG sites. These are the spots on DNA that have cytosine and guanine right next to each other.

Trial Locations

Locations (1)

The Institute for Hormonal Balance; 🇺🇸 Orlando, Florida, United States